Based on our results, we suggest that analysis of the p53 status of a particular tumor and combined treatment with kinesin-5 inhibitor and modulation of survivin expression, either up or down, may improve the efficacy of the anti-cancer treatment. Here, BIRC5 is linked to neoplasm.